vs
Side-by-side financial comparison of NATURES SUNSHINE PRODUCTS INC (NATR) and Wingstop Inc. (WING). Click either name above to swap in a different company.
Wingstop Inc. is the larger business by last-quarter revenue ($183.7M vs $123.8M, roughly 1.5× NATURES SUNSHINE PRODUCTS INC). Wingstop Inc. runs the higher net margin — 16.3% vs 3.3%, a 12.9% gap on every dollar of revenue. On growth, Wingstop Inc. posted the faster year-over-year revenue change (7.4% vs 4.7%). Over the past eight quarters, Wingstop Inc.'s revenue compounded faster (8.6% CAGR vs 5.6%).
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
Wingstop Inc. is an American international fast food chain that primarily sells buffalo wings. Wingstop locations are decorated with a 1930s and 1940s pre-jet aviation theme.
NATR vs WING — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $123.8M | $183.7M |
| Net Profit | $4.1M | $29.9M |
| Gross Margin | 72.5% | 86.5% |
| Operating Margin | 4.3% | 27.4% |
| Net Margin | 3.3% | 16.3% |
| Revenue YoY | 4.7% | 7.4% |
| Net Profit YoY | 1379.4% | — |
| EPS (diluted) | $0.23 | $1.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $183.7M | ||
| Q4 25 | $123.8M | $175.7M | ||
| Q3 25 | $128.3M | $175.7M | ||
| Q2 25 | $114.8M | $174.3M | ||
| Q1 25 | $113.2M | $171.1M | ||
| Q4 24 | $118.2M | $161.8M | ||
| Q3 24 | $114.6M | $162.5M | ||
| Q2 24 | $110.6M | $155.7M |
| Q1 26 | — | $29.9M | ||
| Q4 25 | $4.1M | $26.8M | ||
| Q3 25 | $5.3M | $28.5M | ||
| Q2 25 | $5.3M | $26.8M | ||
| Q1 25 | $4.7M | $92.3M | ||
| Q4 24 | $-321.0K | $26.8M | ||
| Q3 24 | $4.3M | $25.7M | ||
| Q2 24 | $1.3M | $27.5M |
| Q1 26 | — | 86.5% | ||
| Q4 25 | 72.5% | — | ||
| Q3 25 | 73.3% | — | ||
| Q2 25 | 71.7% | — | ||
| Q1 25 | 72.1% | — | ||
| Q4 24 | 72.0% | 85.6% | ||
| Q3 24 | 71.3% | 85.0% | ||
| Q2 24 | 71.4% | 85.4% |
| Q1 26 | — | 27.4% | ||
| Q4 25 | 4.3% | 26.7% | ||
| Q3 25 | 7.0% | 27.9% | ||
| Q2 25 | 3.7% | 25.9% | ||
| Q1 25 | 5.4% | 22.4% | ||
| Q4 24 | 3.8% | 25.9% | ||
| Q3 24 | 4.6% | 24.5% | ||
| Q2 24 | 5.1% | 26.5% |
| Q1 26 | — | 16.3% | ||
| Q4 25 | 3.3% | 15.2% | ||
| Q3 25 | 4.2% | 16.2% | ||
| Q2 25 | 4.6% | 15.4% | ||
| Q1 25 | 4.2% | 53.9% | ||
| Q4 24 | -0.3% | 16.5% | ||
| Q3 24 | 3.8% | 15.8% | ||
| Q2 24 | 1.2% | 17.7% |
| Q1 26 | — | $1.08 | ||
| Q4 25 | $0.23 | $0.99 | ||
| Q3 25 | $0.30 | $1.02 | ||
| Q2 25 | $0.28 | $0.96 | ||
| Q1 25 | $0.25 | $3.24 | ||
| Q4 24 | $-0.02 | $0.91 | ||
| Q3 24 | $0.23 | $0.88 | ||
| Q2 24 | $0.07 | $0.93 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.9M | $128.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $161.6M | — |
| Total Assets | $261.1M | $648.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $128.8M | ||
| Q4 25 | $93.9M | $196.6M | ||
| Q3 25 | $95.6M | $237.6M | ||
| Q2 25 | $81.3M | $227.9M | ||
| Q1 25 | $86.5M | $251.4M | ||
| Q4 24 | $84.7M | $315.9M | ||
| Q3 24 | $78.7M | $84.0M | ||
| Q2 24 | $68.7M | $96.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $161.6M | $-736.8M | ||
| Q3 25 | $166.7M | $-702.6M | ||
| Q2 25 | $163.7M | $-686.0M | ||
| Q1 25 | $167.1M | $-715.0M | ||
| Q4 24 | $161.0M | $-675.6M | ||
| Q3 24 | $162.6M | $-447.5M | ||
| Q2 24 | $156.4M | $-437.5M |
| Q1 26 | — | $648.9M | ||
| Q4 25 | $261.1M | $693.4M | ||
| Q3 25 | $264.8M | $721.0M | ||
| Q2 25 | $254.9M | $708.3M | ||
| Q1 25 | $252.7M | $696.8M | ||
| Q4 24 | $240.9M | $716.2M | ||
| Q3 24 | $245.3M | $484.8M | ||
| Q2 24 | $235.8M | $451.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.9M | — |
| Free Cash FlowOCF − Capex | $7.6M | — |
| FCF MarginFCF / Revenue | 6.1% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | 2.41× | — |
| TTM Free Cash FlowTrailing 4 quarters | $28.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $9.9M | $57.3M | ||
| Q3 25 | $18.5M | $63.9M | ||
| Q2 25 | $4.3M | $6.6M | ||
| Q1 25 | $2.6M | $25.3M | ||
| Q4 24 | $12.2M | $7.7M | ||
| Q3 24 | $9.6M | $69.0M | ||
| Q2 24 | $1.3M | $36.2M |
| Q1 26 | — | — | ||
| Q4 25 | $7.6M | $34.5M | ||
| Q3 25 | $16.8M | $61.7M | ||
| Q2 25 | $3.0M | $-7.8M | ||
| Q1 25 | $1.5M | $17.3M | ||
| Q4 24 | $10.0M | $-8.6M | ||
| Q3 24 | $7.9M | $54.9M | ||
| Q2 24 | $-2.0M | $25.9M |
| Q1 26 | — | — | ||
| Q4 25 | 6.1% | 19.6% | ||
| Q3 25 | 13.1% | 35.1% | ||
| Q2 25 | 2.6% | -4.5% | ||
| Q1 25 | 1.3% | 10.1% | ||
| Q4 24 | 8.5% | -5.3% | ||
| Q3 24 | 6.9% | 33.8% | ||
| Q2 24 | -1.9% | 16.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 13.0% | ||
| Q3 25 | 1.3% | 1.3% | ||
| Q2 25 | 1.2% | 8.2% | ||
| Q1 25 | 1.0% | 4.7% | ||
| Q4 24 | 1.9% | 10.1% | ||
| Q3 24 | 1.5% | 8.7% | ||
| Q2 24 | 3.0% | 6.6% |
| Q1 26 | — | — | ||
| Q4 25 | 2.41× | 2.14× | ||
| Q3 25 | 3.46× | 2.24× | ||
| Q2 25 | 0.81× | 0.25× | ||
| Q1 25 | 0.55× | 0.27× | ||
| Q4 24 | — | 0.29× | ||
| Q3 24 | 2.21× | 2.68× | ||
| Q2 24 | 0.97× | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
WING
| Royalty revenue, franchise fees and other | $87.5M | 48% |
| Advertising fees | $63.3M | 34% |
| Company-owned restaurant sales | $33.0M | 18% |
